ARCHIVES

“Spoiled, Petulant Brat”: BioMarin CEO Fires Off Feisty Emails In Battle Over Access to PARP Inhibitor

This article is from The Cancer Letter archive.

Vol. 39 No. 42 | November 8, 2013

Download PDF Visit The Full Archive

Related Articles

Letter to the Editors: Loss Of ET2 Would Be Disheartening, Member Of Study Section Says

February 20, 1998

In Brief: Little Doubt That DeVita, Frederickson Will Keep Their Jobs; New DCT Projects May Not Be Funded

March 6, 1981

Fewer Young Scientists win NIH Grants, Study

September 30, 1994

Gene Delivery System Targets Tumor Blood Vessels In Dogs

March 27, 2009

Senate Appropriators Reject President’s $228 Million Increase For Cancer Research; House and Senate Report Language

September 18, 2009

Imaging Technique Identifies Consequences Of Mutation

February 24, 2012